Physician profile
Augusto De Leon
NPI 1982664165
$3,408.92
in general payments reported to CMS, 2019-2025
28 companies · $16.80 in 2025
The $16.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.25 · 2022: $642 · 2023: $1,234 · 2024: $1,492 · 2025: $16.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,743.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $502.12 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $486.94 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $383.07 | 2022-2024 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $311.00 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $199.22 | 2022-2024 | Airsupra, Farxiga, Bevespi Aerosphere |
| Lilly USA, LLC | $180.38 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $176.27 | 2022-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.31 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $159.39 | 2022-2024 | Spravato |
| Almatica Pharma LLC | $95.17 | 2022-2023 | Gralise |
| Bayer Healthcare Pharmaceuticals INC. | $92.61 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $92.04 | 2022-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $75.40 | 2024 | Voquezna |
| Exact Sciences Corporation | $73.92 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $73.76 | 2023-2024 | Verquvo, Belsomra, Capvaxive |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $55.92 | 2022-2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $47.23 | 2022 | |
| Lundbeck LLC | $36.54 | 2022-2023 | Rexulti |
| Photonicare INC | $25.11 | 2023 | Otosight Middle Ear Scope |
| Mylan Specialty L.P. | $24.02 | 2024 | Yupelri |
| Agios Pharmaceuticals, INC. | $23.87 | 2024 | |
| Alk-Abello, INC | $23.49 | 2024 | Odactra, Ragwitek, Grastek |
| Biohaven Pharmaceutical Holding Company LTD. | $19.48 | 2022 | |
| Dexcom, INC. | $18.13 | 2024 | Dexcom G6 Transmitter |
| 180 Medical, INC. | $17.31 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.79 | 2024 | Crysvita |
| Medtronic, INC. | $15.39 | 2024 | Intellis Adaptivestim |
| Currax Pharmaceuticals LLC | $13.04 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augusto De Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.